Sugi Predict

Sugi Predict / Compounds / SCHEMBL7187764

SCHEMBL7187764

SCHEMBL7187764

COc1cccc(OC)c1C(=O)[P](=O)c1ccccc1C(=O)c1c(C)c(C)cc(C)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ KCNK3 O14649 2/20 0.38
▸ KCNK9 Q9NPC2 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ ATM Q13315 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ ABCB1 P08183 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ BRPF1 P55201 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ CTSD P07339 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181666 0.93 KCNK3 (0.37) MAPTKMT2AKCNK3KCNK9POLB
SCHEMBL7733699 0.92 ALDH1A1 (0.39) MAPTKMT2AATMMEN1NPC1
SCHEMBL7183272 0.91 CA12 (0.41) KMT2AKCNK3KCNK9POLBCA12
SCHEMBL7188426 0.90 CA12 (0.38) MAPTKMT2AKCNK3KCNK9POLB
SCHEMBL7177390 0.89 CA12 (0.41) MAPTKMT2AKCNK3KCNK9POLB
SCHEMBL7188505 0.88 ABCB1 (0.43) MAPTKMT2AKCNK3KCNK9POLB
SCHEMBL7178036 0.86 KMT2A (0.37) KMT2AKCNK3KCNK9POLBMEN1
SCHEMBL7180488 0.85 ABCB1 (0.43) MAPTKMT2AKCNK3KCNK9POLB
SCHEMBL7188977 0.85 MAPT (0.41) MAPTKMT2AKCNK3KCNK9POLB
SCHEMBL7185356 0.85 ALDH1A1 (0.38) MAPTKMT2AATMMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885KMT2A 1586/4885KCNK3 351/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885KMT2A 956/4885KCNK3 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.